You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Claims for Patent: 10,085,958

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,085,958

Title:	Bromfenac bioavailability
Abstract:	Formulations and methods that provided enhanced bromfenac penetration into ocular tissue when topically administered, compared to the currently available BROMDAY.TM. formulation and method when topically administered. The formulations and methods did so while retaining the patient convenience of a once-daily administration and advantageously lowered the bromfenac concentration dosed to the patient.
Inventor(s):	Padilla; Angel (Aliso Viejo, CA), Baklayan; George (Huntington Beach, CA)
Assignee:	BAUSCH & LOMB PHARMA HOLDINGS CORP. (Rochester, NY)
Application Number:	15/343,457
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,085,958
Patent Claims:	1. An aqueous composition formulated for topical ocular administration, the composition comprising bromfenac as the only active at 0.07% w/v and 1.0% w/v povidone in a formulation buffered at a pH between pH.gtoreq.6.0 and pH<8.0. 2. The composition of claim 1 at pH.gtoreq.7.0 and .ltoreq.7.8. 3. The composition of claim 1 containing 0.07% w/v bromfenac at pH 7.0. 4. The composition claim 1 containing 0.07% w/v bromfenac at pH 7.1. 5. The composition of claim 1 containing 0.07% w/v bromfenac at pH 7.2. 6. The composition of claim 1 containing 0.07% w/v bromfenac at pH 7.3. 7. The composition of claim 1 containing 0.07% w/v bromfenac at pH 7.4. 8. The composition of claim 1 containing 0.07% w/v bromfenac at pH 7.5. 9. The composition of claim 1 containing 0.07% w/v bromfenac at pH 7.6. 10. The composition of claim 1 containing 0.07% w/v bromfenac at pH 7.7. 11. The composition of claim 1 containing 0.07% w/v bromfenac at pH 7.8. 12. The composition of claim 1 further comprising at least one of tyloxapol, sodium sulfite, or benzalkonium chloride. 13. The composition of claim 1 further comprising at least one of tyloxapol at a concentration of 0.01% w/v to 0.5% w/v, sodium sulfite, or benzalkonium chloride at a concentration of .ltoreq.0.01% w/v.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.